Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer By Ogkologos - April 16, 2026 81 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase III study in patients recruited through the PATCH and STAMPEDE-1 trial networks Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026 ESMO Responds to Public Consultation on EU4Health Work Programme for 2027 and Highlights the Importance of Continuing Robust EU Support for Europe’s Beating Cancer... MOST POPULAR New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers May 31, 2018 FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma February 7, 2022 Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal... September 19, 2024 How I Navigated Being a Young Mom During Cancer: A Survivor’s... February 15, 2023 Load more HOT NEWS Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells The Healing Power of Being Outdoors for People With Cancer EMA Recommends Extension of Indications for Pembrolizumab 10 Things I Wish I Knew When I Was First Diagnosed...
